Credits: Canva
Is your teenager skipping breakfast? Why is that happening and what can you do? As per the data from the Centers for Disease Control and Prevention (CDC), which surveyed adolescent health and well-being found that 1 in 4 students in high school ate breakfast, which means 3 in 4 high school students are not eating their breakfast. This data is as per the 2023 survey.
The report describes a 10-year long trend and also recent changes among the two years. The study delved deeper into adolescents' dietary, physical activity and sleep behaviors. The study is also based on a national youth risk behavior survey of a representative sample of students from grade nine to 12.
The study found that while high school students drank slightly less soda and sports drinks and consumed more water, other healthy eating habits declined. In 2023, only 27% of students ate breakfast every day in the past week. The numbers were even lower for female students, with just 22% eating breakfast daily, compared to 32% of male students. Boys were also more likely to eat fruits and vegetables daily and drink water at least three times a day. Poor mental health and lack of physical activity have also been linked to skipping breakfast.
The other findings included a survey across 10-year period, where a decrease in the percentage of students eating fruits from 65% to 55%, eating vegetables, from 61% to 58%, and having breakfast daily from 38% to 27% was noted.
However, there was a positive trend among this, which was in children drinking plain water at least three times a day, which increased from 49% to 54% from when the survey began in 2015.. There were fewer students who also said that they drank soda in 2023 than in 2013. On an average, in 2013, around 22% students avoided soda, whereas in 2023, 31% students avoided it.
The report also emphasized that a healthy diet, along with daily physical activity and sufficient sleep further contributes to a healthy lifestyle. “The 10-year trends from 2013 to 2023 also show a decline in healthy dietary, physical activity, and sleep behaviors,” the survey reported.
While there is no one straightforward answer to it, psychologists and those who study children, believe that for many high school going kids, it is the easiest time to skip a meal. This is because they are caught between rushing to school, or not just that hungry in the morning. So for them, to sit down to have a breakfast may seem hassle and something they would have to take time out from their busy schedule. They at this age also prioritize their extra-curricular activities.
There has also been a shift in their circadian rhythm, and most teens cannot fall asleep before 11 pm, or even at midnight. Which means they wake up tired and struggle to do things right in the morning, which is why they choose to skip breakfast or give extra minutes to any other activities.
There is of course another, more popular reason, to lose weight. While experts and studies, like the one published in the Journal of Nutrition that found skipping breakfast leads to higher levels of hunger hormones, the students still feel the need to do this. However, it could lead to a slow metabolism, prompt the body to conserve energy and burn fewer calories, weight gain and deprive yo off the essential nutrients like calcium, iron, and vitamin D.
Without a morning breakfast, your blood sugar might drop too, which can increase irritability and stress, along with including the risk of depression in teenage.
Credit: AI-generated image
The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.
The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.
RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.
The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.
Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.
Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.
Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.
The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.
According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.
Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.
The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.
Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients
The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.
The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.
Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.
Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.
The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.
Credit: AI-generated image
Breckenridge Pharmaceutical, Inc. has announced a voluntary nationwide recall of a batch of Propranolol Hydrochloride Extended-Release Capsules, USP 60 mg in the US over concerns that the medication may contain metal particles.
The recall, announced on November 16, 2026, covers one lot of the blood pressure medication manufactured by Adare Pharma Solutions. The company initiated the recall after identifying a possible contamination linked to an intermediate material used in the affected batch.
According to the company's recall notice, the contaminated material was suspected to be the source of metal contamination identified in a separate lot that was not released into the market.
The company has warned that taking capsules from the affected lot could cause physical injuries to soft tissues in the body.
According to the recall notice, use of the affected product could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine."
However, Breckenridge Pharmaceutical stated that it was not aware of any adverse events related to the recall at the time of the announcement.
The affected products were distributed to wholesalers and pharmacies across the US between October 26 and November 4, 2026.
Also read: From 4 To 100 Kratom Capsules A Day: Woman Shares Warning Signs Of Addiction
The recall is limited to a specific batch of 60 mg Propranolol Hydrochloride Extended-Release Capsules. The details are:
Those who have been prescribed the pill between the dates mentioned above are advised to check the product packaging and lot number to determine whether their medication is part of the recall.
Also read: Popular Anti-Anxiety Capsules Recalled Over Salmonella Fears: What Should Patients Know
Breckenridge Pharmaceutical has advised consumers to immediately stop taking the medication from the affected lot and contact their physician or healthcare provider for medical advice for obtaining a replacement.
"Consumers should return any unused portion of the affected product to the pharmacy where it was obtained," the company's announcement said.
Patients should also return any unused capsules from the recalled batch to the pharmacy where they purchased the medication. Anyone who has experienced health problems that could be due to the recalled medicine should contact their healthcare provider.
Pharmacies, wholesalers and other retailers have been instructed to check their inventories, quarantine the affected products and stop distributing or dispensing them.
Consumers seeking additional information about the recall can contact Qualanex, the company's designated recall service provider, at 1-855-736-0807 or email recall@qualanex.com. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA).
Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests
Propranolol belongs to a class of medicines called beta-blockers. It works by reducing the effects of certain stress hormones on the heart, thereby slowing the heart rate and reducing blood pressure.
The medication is commonly prescribed to manage high blood pressure and other cardiovascular conditions. It is also used for certain heart rhythm disorders, angina and migraine prevention.
The extended-release formulation is designed to release the medicine gradually over time, allowing effects that last long.
Propranolol's recall is the latest in a series of recent blood pressure medication recalls, including a recent one involving Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets. They were recalled as they did not dissolve properly. A while go, Chlorthalidone tablets were also recalled for the same reason.
Credit: iStock
Could chewing gum one day help fight cancer? Researchers at the University of Pennsylvania in the US have developed an experimental gum made from lablab beans, also known as Indian beans, that targets human papillomavirus (HPV) and harmful oral bacteria associated with head and neck cancer.
In laboratory tests using oral samples from cancer patients, extracts of the gum reduced HPV levels by up to 93%. An enhanced version also reduced two harmful bacterial species to nearly undetectable levels without affecting the beneficial bacteria tested.
The experimental gum builds on the team's earlier research into lablab beans. It contains FRIL, a naturally occurring plant protein with antiviral properties.
Researchers tested gum extracts against microorganisms in oral samples collected from patients with head and neck cancer.
The results published in Scientific Reports journal showed:
The researchers also developed an enhanced version containing protegrin, an antimicrobial peptide. Peptides are short chains of amino acids, the building blocks of proteins.
A single dose of the enhanced gum extract reduced two targeted bacterial species, Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn), to nearly undetectable levels.
Also read: HPV Vaccines Can Prevent Head And Neck Cancers In Men, Says Study
The experimental formulation selectively targeted harmful bacteria while leaving the beneficial bacterial populations examined in the study largely unaffected.
The oral microbiome, which consists of microorganisms living inside the mouth, plays an important role in maintaining oral health.
Cancer treatments such as radiation therapy can disrupt this microbial balance, reducing beneficial bacteria and encouraging the growth of potentially harmful microorganisms, including Candida albicans, a type of yeast.
The researchers suggest that selectively targeting harmful microbes while preserving beneficial ones could be particularly useful for patients undergoing cancer treatment.
Read More: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours
The researchers believe the findings warrant further investigation through human clinical trials. They envision the technology potentially being used alongside existing cancer treatments or as a preventive approach to limit infections.
"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," Daniell said.
He said the findings support advancing these therapies into clinical trials as additional treatments or as prophylaxis to prevent infection and transmission.
Prophylaxis refers to measures taken to prevent a disease or infection before it occurs.
The plant-based technology could also offer a potentially affordable way to deliver protective proteins directly into the mouth.
However, the findings should be interpreted cautiously. The researchers tested gum extracts on patient samples under laboratory conditions. They have not established whether chewing the gum produces the same results in people or whether reducing these microorganisms can prevent cancer or improve treatment outcomes.
Human clinical trials will be needed to establish its safety and effectiveness. For now, the bean-based gum remains experimental and is not a proven cancer-prevention or treatment option.
© $2026 Times Horizon Private Limited